Precision BioSciences Inc (DTIL)

[jondoeuk]

Looks as though the entire gene editing market took a hit with the news of Allogene’s HOLD for their Car-T program…I am not certain this is a bad thing at all for Precision Biosciences. Time will tell but this could be a process specific issue.

In response, DTIL issued this https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-statement-safety-its-allogeneic-car-t

Balanced chromosomal abnormalities can be due to insertions or deletions of genes.

The chromosomal abnormality was on chromosome 14, the same chromosome as one of the two genes (TCR) edited during the manufacturing process.

This could be a misfire that is known to occur more often with CRSPR process.

CRISPR? In case you weren't aware, ALLO use CLLS's TALEN.

The anemia may be an autoimmune reaction triggered by the anomaly.

Hard to say at this stage, but we know the patient subsequently developed progressive pancytopenia (reported in those after auto CAR-T therapies), and a bone marrow biopsy showed aplastic anaemia, before they underwent an allogeneic stem cell transplantation.

ARCUS may be a safer play when it comes to these types of risks.

Yes, as should iPSC-derived products. ALLO is working with Notch https://www.globenewswire.com/news-release/2019/11/05/1940970/0/en/Allogene-Therapeutics-and-Notch-Therapeutics-Announce-Collaboration-to-Research-and-Develop-Induced-Pluripotent-Stem-Cell-iPSC-Derived-Allogeneic-Therapies-for-Hematologic-Cancer-I.html